Arkolith/Insider Trading/HRTX/Form 4

Manhard Kimberly

EVP, Drug Development, DirectorHERON THERAPEUTICS, INC. /DE/ (HRTX) · full profile →Form 4 · filed May 4, 2022
Net Selling
Open-Market Buys
$0
Open-Market Sells
$7K
Net Open-Market Flow
-$7K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 3, 2022Sell(S)2K$4.76$7K11K
Apr 29, 2022Other(J)2K$3.84$6K12K

Transaction Codes

S
Open-market sale
J
Other acquisition / disposition

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-22-027232) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML